Research
Hormonal
Home sleep monitoring devices can distinguish between obstructive and central sleep apnea phenotypes using cardiopulmonary coupling metrics, even without being approved for diagnosis.
If you have known sleep apnea, some advanced home monitors (like M1/SleepImage) may help distinguish between obstructive and central types using heart rate variability patterns, but this is not a diagnostic tool. Consult a physician for diagnosis and treatment.
GoodQualifiesMEDIUM confidence
Thus, although the device is not approved for the diagnosis of sleep apnea, within known sleep apnea patients some distinction can be achieved between obstructive and central phenotypes.
Why this rating
The paper cites specific studies showing this distinction, but notes the device is not approved for diagnosis.
Source
Recent Developments in Home Sleep-Monitoring Devices
Jessica M. Kelly et al. · ISRN Neurology · 2012
DOI 10.5402/2012/768794
narrative_reviewCited 180×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Most commercially available consumer sleep monitors (e.g., Fitbit, Lark, Sleep Cycle) lack published validation studies comparing their sleep-wake metrics or smart-alarm features to gold-standard PSG or standard actigraphy.Strong
- Longitudinal home sleep monitoring using portable devices enables the identification of individual sleep patterns and correlations with modifiable behaviors (e.g., exercise, diet, stress), facilitating personalized health optimization and treatment strategies.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →